SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: Bull-like who wrote (305)8/29/1998 12:26:00 AM
From: Anthony Wong  Respond to of 642
 
Supermarkets, Utilities, REITs and Drug Companies Among Sectors Seen As Havens
August 28, 1998 4:59 PM


By Janet Morrissey and Brian Steinberg

NEW YORK (Dow Jones)--Large supermarket chains,
utilities, real-estate investment trusts, homebuilders and
drug companies are among the sectors observers are
touting as good defensive plays during the volatile broad
market.

"Supermarkets are totally domestic and sell the
necessities of life," said Prudential Securities Inc. analyst
George Thompson. "They perform well whether the
economy is good or bad."

Thompson noted that supermarkets have little or no
exposure to Asia or Russia. And aside from their
predictability, he said, many are posting double-digit
earnings growth.

"Many have had significantly better growth rates than the
S&P," he said.

Thompson cited larger chains such as Kroger Co. (KR),
Albertson's Inc. (ABS) and Safeway Inc. (SWY) as
good bets during the market downturn.

Year to date, Kroger's shares are up 39.3%,
Albertson's are up 12.3% and Safeway's are up 36.8%,
he said.

BT Alex. Brown Inc. analyst Edward Tirello names
utilities as the best havens.

"Anytime the market gets jittery, these are the ones you
go to first," he said. "They hold up better and they go
down less."

But Janney Montgomery Scott analyst David Schanzer
cautioned that it's an old myth to assume that utilities are
real defensive plays.

"I continue to warn against the use of the electric utility
group as a sound defensive investment," he said. "It's not
what it used to be."

Schanzer said "re-regulation and competition" changed
the utility landscape, and some companies are getting
involved in overseas investments that haven't panned
out.

Indus,Mall,Certain Office REITs Good Bets

Legg Mason Wood Walker Inc. analyst Ronald Tanner,
who covers about 25 electric utilities, noted that utility
stocks have taken a hit.

"They're rolling in sympathy with people getting out of
the market, but they are more attractive on a relative
basis," he said.

REITs historically have been seen as defensive stocks
because of their predictable earnings and high-yielding
dividends. But investors began viewing them as growth
stocks after they posted returns of 36% in 1996 and
19% in 1997, according to the National Association of
Real Estate Investment Trusts.

In 1998, investors, worried about slowing growth and
talk of overbuilding in certain sectors, began pulling out,
causing REIT prices to tumble.

The Morgan Stanley REIT index was off 15.4% at the
close of business Wednesday on a year-to-date basis,
the S&P was up 8.48% and the Russell 2000 was off
16.23%, according to Morgan Stanley.

But despite REITs' battered share prices, Morgan
Stanley analyst Greg Whyte said REITs are a good
haven in a falling market.

"The dividend is still attractive in this environment. ... Its
yield is better than a bond or utility," he said.

Within the REIT world, he said industrial and warehouse
distribution companies are the most attractive havens
because they usually have tenants with good-quality
credit on long-term leases. He also cited office REITs
that operate in central business districts that have
barriers to entry, such as New York, Boston and San
Francisco.

CIBC Oppenheimer Corp. analyst Jordan Heller also
believes the "high yield" is a compelling reason for
investors to seek out REITs in a falling market. He
named community shopping center REITs, which sell
necessities, and manufactured home community REITs,
with their low tenant turnover, as especially attractive in
a downturn.

Homebuilders, Drug Cos. Called Attractive

Morgan Stanley's Greg Whyte cited
industrial/warehouse REITs such as Duke Realty
Investments Inc. (DRE), Weeks Corp. (WKS), Spieker
Properties Inc. (SPK) and ProLogis Trust (PLD), and
office REITs, such as Boston Properties Inc. (BXP),
Crescent Real Estate Equities Co. (CEI) and Equity
Office Properties Trust (EOP), as examples of REITs in
good defensive sectors.

Chateau Communities Inc. (CPJ) and Sun Communities
Inc. (SUI) and Manufactured Home Communities Inc.
(MHC) are examples of manufactured-home community
stocks that could be good havens, according to CIBC
Oppenheimer's Heller.

Homebuilding stocks are also being touted as good
defensive plays to help ride out turbulence in the broad
market, at least in the short-term.

Homebuilders have no exposure to Asia or Russia and
have been reaping the benefits of low interest rates,
good job growth, surging consumer confidence and a
robust economy. In the past two quarters, most crashed
through Wall Street earnings projections as a result of
healthy demand, fewer sales incentives and rising house
prices. For example, Pulte Corp. (PHM) beat First
Call's first-quarter numbers by 30 cents a share, while
Ryland Group Inc. (RYL) exceeded second-quarter
estimates by 29 cents.

Although most posted record home orders in the latest
quarter, which generally translate into revenues two or
three quarters down the line when the home closes,
growth has slowed over the past couple of months,
prompting some investors to take notice.

Still, Merrill Lynch & Co. analyst Bob Curran
anticipates orders will continue to rise at a low
double-digit or high single-digit pace through the end of
the year and 5% to 10% in 1999. He predicts higher
home prices will offset the slowdown. Barring a
recession, he said, he sees homebuilders continuing to
post good numbers through most of 1999.

Curran named Kaufman & Broad Home Corp. (KBH),
Lennar Corp. (LEN), D.R. Horton Inc. (DRI) and
luxury builder Toll Brothers Inc. (TOL) has examples of
builders with good growth potential.

Although the problems in Asia and Russia don't affect
homebuilders, economic turbulence in Latin America
could throw an economic wrench into the U.S.
economy, Curran said. And if that happened, he said,
homebuilders could be affected.

Credit Suisse First Boston Corp. analyst Ivy Zelman
said the homebuilding sector is currently trading at only
9.5 times estimated 1999 earnings, compared with S&P
stocks, which trade, on average, at a multiple of 22 to
24.

Zelman said the low valuation along with the group's
lack of Asian exposure and healthy earnings growth
make building stocks attractive picks. But she cited
growing concerns that builders may be nearing the end
of their cycle. She sees building stocks as good
short-term investments - for three to six months, not the
long term.

Pharmaceutical and biotechnology stocks are also being
dubbed as good defensive plays as a result of their
stable earnings stream, steady market demand and
limited exposure to emerging markets.

Analysts are touting stocks such as Pfizer Inc. (PFE), Eli
Lilly & Co. (LLY) and Merck & Co. (MRK) as safe
havens in the pharmaceutical world.


Analysts Point To Baby Bells, GTE

In the mostly volatile telecommunications sector, the
Baby Bell operators and GTE Corp. (GTE) are
nonetheless considered a safe haven for defensive
investors.

Despite efforts to expand overseas, the Bells still derive
90% or more of their revenue from the U.S., analysts
say, which protects investors from global volatility.

Additionally, these stocks offer high annual dividends
relative to other large-cap stocks. These yields range
from 2.2% for BellSouth Corp. (BLS) to 4.3% for U S
West Inc. (USW).

"Earnings for these companies (the Bells and GTE) are
extremely visible and grow at a pace that exceeds the
general market," said Robert Donahue, an analyst at
Salomon Brothers Asset Management.

Donahue added that both Bell Atlantic Corp. (BEL) and
GTE, which agreed last month to merge, are at
historically inexpensive levels and are likely to gain in
either a bear or bull market.
- Janet Morrissey; 201-938-2118
- Brian Steinberg; 201-938-5218
- Craig Karmin contributed to this report.

Defense Industry Stks Seen As Good Bets

Morgan Stanley Dean Witter aerospace analyst Pierre
Chao said stocks that benefit from the defense industry
shouldn't be overlooked. He noted that the federal
government approved an increase in defense spending
for the first time in more than a decade, boosting
spending to $49 billion in 1999 from $45 billion. He
added that it's expected to climb to $60 billion by 2002.

"The defense budget is not based on the economy or
interest rates," he said. He cited Lockheed Martin Corp.
(LMT), Raytheon Co. (RTNA,RTNB), and Alliant
TechSystems Inc. (ATK) as stocks that benefit from the
defense industry.

- Janet Morrissey 201-938-2118

- Brian Steinberg 201-938-5218

smartmoney.com




To: Bull-like who wrote (305)9/2/1998 3:26:00 PM
From: Anthony Wong  Respond to of 642
 
FDA panel's tamoxifen nod seen lifting Lilly drug
Wednesday September 2, 2:25 pm Eastern Time

By Kevin Drawbaugh

CHICAGO, Sept 2 (Reuters) - The Eli Lilly & Co. (LLY - news) drug Evista is likely to get a boost from a favorable ruling Wednesday on the Zeneca Group Plc (ZEN - news) drug tamoxifen by a regulatory panel in Washington, analysts said.

Both compounds come from the same chemical family and are seen by some as the first drugs able to prevent breast cancer.

A U.S. Food and Drug Administration advisory committee voted to recommend approval of Zeneca's request to market tamoxifen as a breast cancer preventative.

The oncologic drugs advisory committee's support of tamoxifen is not binding, but the FDA usually heeds committees' advice, making tamoxifen's ultimate approval likely.

''That should be very helpful to Lilly,'' said EVERENSecurities analyst Jeffrey Kraws.

At midday on the New York Stock Exchange, Lilly shares were up 1-2/16 at 70-9/16 for a gain this year of about 2 percent, well off the U.S. drug industry average year-to-date gain of more than 20 percent. Shares in Zeneca were up 2-5/8 at 40-1/2, lifted by the committee ruling, analysts said.

Both tamoxifen and Evista are selective estrogen receptor modulators, or SERMs, thought to alter the action of the hormone estrogen in females. Tamoxifen is already sold by Zeneca, a British company, as an anti-cancer drug under the brand-name Nolvadex.

Evista, known generically as raloxifene, is sold by Lilly as a preventative for bone-brittling osteoporosis. But its sales since launch in January have not met market expectations, and Lilly's
stock has suffered as a result, making Wall Street hungry for any hopeful signs on new uses for Evista.

''Because there's been so much disappointment, any glimmer of good news would have an impact,'' said Cowen & Co. pharmaceutical industry analyst Stephen Scala.

A National Cancer Institute study of 13,388 women at high risk for breast cancer showed tamoxifen reduced incidence of the disease by 45 percent. The results were so compelling that the study was halted early in April to allow patients in the control group to switch from dummy pills to tamoxifen.

Concerns about the drug's side-effects lingered, however, with a group of cancer activists urging the FDA panel to reject Zeneca's request.

Dr. Samuel Epstein, chairman of the Cancer Prevention Coalition and a professor at the University of Illinois, submitted a statement to the committee opposing Zeneca.

''Tamoxifen is a highly potent carcinogen,'' Epstein said in his statement. ''Disturbingly, women in the (cancer institute) trial were not informed of the clear evidence of these risks.''

He added, ''Additionally, there are serious questions as to whether tamoxifen actually reduced the incidence of breast cancer or merely delayed its onset. Two articles published on July 11 in the highly prestigious journal, The Lancet, reported no evidence of breast cancer prevention by tamoxifen in two major European trials.''

Tamoxifen is a 35-year-old drug that no longer has patent protection in Europe and is scheduled to lose its patent protection in the United States in 2002, limiting its potential as a major new source of
revenue for Zeneca, analysts said.

Indianapolis-based Lilly said it will begin a clinical trial this fall directly comparing Evista and tamoxifen. The trial will involve 20,000 women at increased risk for breast cancer.

Interim data from earlier breast cancer trials with Evista showed it reduced the incidence of the disease without some of the side-effects seen in tamoxifen trials.



To: Bull-like who wrote (305)9/3/1998 4:36:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 642
 
Synaptic Rises as Drug Moves to Late-Stage Testing (Update1)

Bloomberg News
September 3, 1998, 1:57 p.m. ET

Synaptic Rises as Drug Moves to Late-Stage Testing (Update1)

(Adds executive's comments in 5th through 9th paragraphs.)

Paramus, New Jersey, Sept. 3 (Bloomberg) -- Synaptic
Pharmaceutical Corp. shares rose as much as 26 percent after the
drug research company and Eli Lilly & Co. said the migraine drug
on which they're collaborating will advance into Phase III, or
late-stage, testing.

Synaptic rose 2 1/8 to 13 in midafternoon trading of 253,700
shares, more than seven times the three-month daily average.
Earlier, shares touched 13 11/16. Lilly, maker of the world's
best-selling antidepressant drug, rose 3 1/8 to 72 3/8.

Paramus, New Jersey-based Synaptic and Indianapolis-based
Lilly will form a product team to research development of the
drug, which treats migraines without cardiovascular side effects
associated with products currently on the market, Synaptic said.

''We have several programs with Lilly in various stages to
develop other compounds,'' said Kathleen P. Mullinix, president
and chief executive of Synaptic. ''This migraine drug is the most
advanced we have so far.''

Synaptic and Lilly, which have been working on the migraine
treatment drug since 1994, are also working on a drug to prevent
migraine headaches, another to help smokers quit, and drugs to
treat obesity and depression, Mullinix said. ''We only go after
drugs for very large markets,'' she said.

While Mullinix said that Synaptic will receive royalties for
the drugs once they get to market, she declined to disclose any
figures.

Synaptic is also working with Merck & Co. on a prostate
drug, with Novartis AG on an obesity drug, and with Warner-
Lambert Co. on drugs to treat obesity and diabetes.

''We do the high-tech research and the big drug companies
take care of testing and marketing,'' she said.

Phase I trials typically are aimed at measuring the safety
of new drugs, not efficacy, while Phase II studies are designed
to measure efficacy and determine optimal dosages. Phase III
studies, the final stage, are designed to show statistically
significant safety and efficacy.

--Anthony Massucci in the Princeton newsroom (609) 279-4048 sgp